Methylene blue relieves the development of osteoarthritis by upregulating LncRNA MEG3

31Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

Abstract

Methylene blue (MB) is a long-term inhibitor of peripheral nerve axons, thereby alleviating or permanently eliminating pain. However, it remains unknown whether MB is safe and effective method of treating osteoarthritis (OA). MB was injected into the knee joints of rabbits and they were monitored for any histological structural changes. The results revealed no evident changes in the histological structure of the normal knee joint following injection of 1 mg/kg MB at 1, 4, 8 and 24 weeks post-injection. Compared with the vehicle control, MB treatment significantly enhanced the weight distribution and significantly decreased the swelling ratio of the rabbits. Additionally, levels of long non-coding RNA (lncRNA) maternally expressed 3 (MEG3) mRNA were significantly increased following treatment with MB, but the protein expression of P2X purinoceptor 3 (P2X3) was significantly suppressed compared with the vehicle control. The levels of interleukin (IL) 6, tumor necrosis factor (TNF)α, IL-1β and IL-8 were significantly suppressed following MB treatment, indicating that MB protects against OA progression. It was also revealed that MEG3 overexpression significantly suppresses levels of P2X3 protein. ELISA indicated that the MEG3-induced reduction of IL-6, TNFα, IL-1β and IL-8 expression was significantly reversed following P2X3 overexpression. Therefore, the results of the present study demonstrated that MB is an effective method of treating OA-associated pain by upregulating lncRNA MEG3 levels. Additionally, lncRNA MEG3 relieves the OA-associated pain and inflammation in a rabbit model of OA by inhibiting P2X3 expression.

References Powered by Scopus

Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-ΔΔC</sup>T method

146861Citations
N/AReaders
Get full text

Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomised, placebo-controlled clinical trial

1088Citations
N/AReaders
Get full text

Long noncoding RNA related to cartilage injury promotes chondrocyte extracellular matrix degradation in osteoarthritis

172Citations
N/AReaders
Get full text

Cited by Powered by Scopus

LncRNA MEG3 Inhibits the Degradation of the Extracellular Matrix of Chondrocytes in Osteoarthritis via Targeting miR-93/TGFBR2 Axis

38Citations
N/AReaders
Get full text

MEG3 promotes proliferation and inhibits apoptosis in osteoarthritis chondrocytes by miR-361-5p/FOXO1 axis

38Citations
N/AReaders
Get full text

Comparative study regarding the properties of methylene blue and proflavine and their optimal concentrations for in vitro and in vivo applications

34Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Li, X., Tang, C., Wang, J., Guo, P., Wang, C., Wang, Y., … Wu, H. (2018). Methylene blue relieves the development of osteoarthritis by upregulating LncRNA MEG3. Experimental and Therapeutic Medicine, 15(4), 3856–3864. https://doi.org/10.3892/etm.2018.5918

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

50%

Researcher 5

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

62%

Chemistry 2

15%

Nursing and Health Professions 2

15%

Chemical Engineering 1

8%

Article Metrics

Tooltip
Mentions
News Mentions: 1
Social Media
Shares, Likes & Comments: 1

Save time finding and organizing research with Mendeley

Sign up for free